SCHEMBL16635935

SCHEMBL16635935

COC(=O)C1CCCCC1c1csc(Oc2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.49
SLC6A4 P31645 3/20 0.49
CPT1A P50416 8/20 0.44
CPT2 P23786 5/20 0.44
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
CNR2 P34972 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
SLC6A3 Q01959 2/20 0.36
CPT1B Q92523 2/20 0.36
KCNQ1 P51787 1/20 0.36
SCN9A Q15858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16635933 1.00 SLC6A2 (0.49) SLC6A2SLC6A4CPT1ACPT2FNTA
SCHEMBL16635682 0.88 FNTA (0.44) CPT1ACPT2FNTAFNTBHCRTR1
SCHEMBL16635949 0.79 SLC6A2 (0.48) SLC6A2SLC6A4CPT1ACPT2FNTA
SCHEMBL16635947 0.79 SLC6A2 (0.48) SLC6A2SLC6A4CPT1ACPT2FNTA
SCHEMBL16636099 0.78 SLC6A2 (0.45) SLC6A2SLC6A4CPT1ACPT2CNR2
SCHEMBL16635781 0.73 SLC6A2 (0.46) SLC6A2SLC6A4CPT1A
SCHEMBL16635783 0.73 SLC6A2 (0.46) SLC6A2SLC6A4CPT1A
SCHEMBL18010297 0.72 HCRTR1 (0.36) CPT1ACPT2HCRTR1HCRTR2CPT1B
SCHEMBL16636110 0.72 HCRTR1 (0.36) CPT1ACPT2HCRTR1HCRTR2CPT1B
SCHEMBL12354221 0.72 SLC6A2 (0.81) SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015051479-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ SLC6A2 4308/4885SLC6A4 4386/4885CPT1A 4224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.